Ferrante, M., Peyrin-Biroulet, L., Arkkila, P., Armuzzi, A., Colombel, J., Danese, S., . . . Atreya, R. (2025). Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: A systematic literature review and meta-analysis. Therapeutic Advances in Gastroenterology, 18, 1. https://doi.org/10.1177/17562848251383767
Chicago Style (17th ed.) CitationFerrante, Marc, et al. "Treatment Discontinuation Rates Due to Lack of Efficacy Through 1 Year of Maintenance Treatment with Vedolizumab or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Meta-analysis." Therapeutic Advances in Gastroenterology 18 (2025): 1. https://doi.org/10.1177/17562848251383767.
MLA (9th ed.) CitationFerrante, Marc, et al. "Treatment Discontinuation Rates Due to Lack of Efficacy Through 1 Year of Maintenance Treatment with Vedolizumab or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Meta-analysis." Therapeutic Advances in Gastroenterology, vol. 18, 2025, p. 1, https://doi.org/10.1177/17562848251383767.
